✦ LIBER ✦

MP-14.11: First-Ever Survey on the Epidemiology of Renal Cell Carcinoma in Brazil

✍ Scribed by S. Zequi; A. Nardi; S. Glina; J. Almeida

Book ID: 116951813
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 170 KB
Volume: 74
Category: Article
ISSN: 0090-4295
DOI: 10.1016/j.urology.2009.07.862

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

MP57-01 IMPORTANCE OF THE THERAPEUTIC RE

MP57-01 IMPORTANCE OF THE THERAPEUTIC RESPONSIVENESS OF PRIMARY RENAL TUMOR ON FIRST CT EVALUATION FOR THE PROGNOSIS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA: SIGNIFICANCE OF TUMOR SIZE, NECROSIS, HISTOLOGY AND CONTRAST-ENHANCING ATTENUATION

✍ Han KIM, Sung; Joung, Jae Young; Lee, Kang Hyun; Seo, Ho Kyung; Chung, Jinsoo 📂 Article 📅 2014 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 144 KB

826 THE EFFECT OF RADICAL VERSUS PARTIAL

826 THE EFFECT OF RADICAL VERSUS PARTIAL NEPHRECTOMY ON OTHER-CAUSE MORTALITY IN PATIENTS WITH T1A RENAL CELL CARCINOMA: RESULTS FROM THE SURVEILLANCE, EPIDEMIOLOGY AND END RESULTS DATABASE

✍ Lughezzani, Giovanni; Jeldres, Claudio; Budaus, Lars; Shariat, Shahrokh F.; Libe 📂 Article 📅 2010 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 42 KB

Comment on ‘Costs of managing adverse ev

Comment on ‘Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib’

✍ Charbonneau, C; Sandin, R 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 155 KB

7126 What is the impact of subsequent an

7126 What is the impact of subsequent antineoplastic therapy on overall survival (OS) following first-line bevacizumab (BEV)/interferonalpha2a (IFN) in metastatic renal cell carcinoma (mRCC)? – Experience from AVOREN

✍ Bracarda, S.; Bellmunt, J.; Negrier, S.N.; Melichar, B.; Ravaud, A.; Jethwa, S.; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 51 KB

CN8 METHODOLOGICAL ISSUES OF CONTROL ARM

CN8 METHODOLOGICAL ISSUES OF CONTROL ARM ADJUSTMENTS FOR COMPARATIVE EFFECTIVENESS ASSESSMENTS: AN EXAMPLE BASED ON THE COMPARISON OF FIRST-LINE BEVACIZUMAB + INTERFERON ALPHA-2A VS SUNITINIB IN RENAL CELL CARCINOMA

✍ B Schwander; GH Mickisch; S Walzer; U Siebert 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB

Effect of comorbidity on risk of venous

Effect of comorbidity on risk of venous thromboembolism in patients with renal cell carcinoma11The project described was supported by the National Center for Research Resources, United States, through Grant KL2TR000084 the National Center for Advancing Translational Sciences, United States, through Grant KL2TR000084 and the National Institutes of Health, United States, through Grant KL2TR000084, and a grant from the Danish Cancer Society (R73-A4284-13-S17) and from the Karen Elise Jensen Foundation. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH and the Clinical Epidemiological Research Foundation.

✍ Smith, Angela B.; Horvath-Puhó, Erzsébet; Nielsen, Matthew E.; Lash, Timothy L.; 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 220 KB